{"brief_title": "Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)", "brief_summary": "The objective is to compare the safety and efficacy of the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1) PegIntron 1.5 \u00b5g/kg/wk in combination with weight based REBETOL (800-1400 mg/day); (2) PegIntron 1\u00b5g/kg/wk in combination with weight based REBETOL (800-1400 mg/day); and (3) PEGASYS 180 \u00b5g/wk plus COPEGUS 1000-1200 mg/day.", "detailed_description": "PegIntron Dose will be administered once weekly subcutaneously on the same day of the week: Screening 2 Weight 40-50 kg Volume to Inject (mL) 0.22; Screening 2 Weight 51-60 kg Volume to Inject (mL) 0.28; Screening 2 Weight 61-75 kg Volume to Inject (mL) 0.33; Screening 2 Weight 76-85 kg Volume to Inject (mL) 0.41; Screening 2 Weight 86-104 kg Volume to Inject (mL) 0.48; Screening 2 Weight 105-125 kg Volume to Inject (mL) 0.58 from two vials REBETOL Dosage (for Use With PegIntron): Screening 2 Weight 40-65 kg Daily Dose 800 mg; Screening 2 Weight >65-85 kg Daily Dose 1000 mg; Screening 2 Weight >85-105 kg Daily Dose 1200 mg; Screening 2 Weight >105-125 kg Daily Dose 1400 mg The PEGASYS dose of 1 mL (180 \u00b5g) will be administered once weekly subcutaneously on the same day of the week COPEGUS Dosage (for Use With PEGASYS): Screening 2 Weight <75 kg Daily Dose 1000 mg; Screening 2 Weight > or = 75 kg Daily Dose 1200mg NOTE: Double Blind for PegIntron; Open Label for REBETOL, PEGASYS and COPEGUS NOTE: REBETOL is the Schering-Plough brand name for ribavirin. COPEGUS is the Hoffman-La Roche brand name for ribavirin.", "condition": ["Hepatitis C, Chronic"], "intervention_type": ["Biological", "Biological", "Drug", "Biological", "Drug"], "intervention_name": ["PegIntron (peginterferon alfa-2b; SCH 54031)", "PegIntron (peginterferon alfa-2b; SCH 54031)", "REBETOL (ribavirin; SCH 18908)", "PEGASYS (peginterferon alfa-2a)", "COPEGUS (ribavirin)"], "description": ["1.5 ug/kg/week subcutaneously (SC) for 48 weeks", "1.0 ug/kg/week SC for 48 weeks", "weight based dose 800-1400 mg/day orally (PO) for 48 weeks", "180 ug/week SC administered for 48 weeks", "1000-1200 mg/day PO for 48 weeks"], "arm_group_label": ["PegIntron 1.5 ug/kg/wk plus REBETOL", "PegIntron 1.0 ug/kg/wk plus REBETOL", "PegIntron 1.5 ug/kg/wk plus REBETOL", "PegIntron 1.0 ug/kg/wk plus REBETOL", "PEGASYS 180 ug/wk Plus COPEGUS", "PEGASYS 180 ug/wk Plus COPEGUS"], "other_name": ["PegIntron", "PegIntron", "REBETOL [the Schering-Plough brand name for ribavirin]", "PEGASYS", "COPEGUS [the Hoffman-La Roche brand name for ribavirin]"], "criteria": "INCLUSION CRITERIA: - Previously untreated adults with chronic hepatitis C (hepatitis C virus ribonucleic acid [HCV RNA] quantitative polymerase chain reaction [qPCR] plasma positive) - Individuals with HCV genotype 1 (mixed 1a/1b is acceptable) - Compensated liver disease - Pretreatment liver biopsy slides available - Adults aged 18-70 - Individuals weighing 88-275 pounds (40-125 kg) - Free from substance abuse for past 2 years - Those suffering from diabetes and/or hypertension must have normal eye exams and retinal photographs (these will be done as part of the study before hepatitis C treatment is given) - Patients and partners of patients willing to use adequate contraception during the course of the study - Hematology laboratory results of: - Hemoglobin (HGB) \u2265 12 g/dL for females or \u2265 13g/dL for males - White Blood Cell Count (WBC) \u2265 3,000/mm^3 - Neutrophils \u2265 1,500/mm^3 - Platelets \u2265 80,000/mm^3 - Chemistry laboratory results of: - Normal Thyroid Stimulating Hormone (TSH), albumin, creatinine, and direct bilirubin - Antinuclear antibody (ANA) \u2264 1:320 - Fasting Glucose 70-140 mg/dL Note: If glucose levels are between 116-140 mg/dL or an individual has diabetes, glycosylated hemoglobin [HbA1C] must be \u2264 8.5% EXCLUSION CRITERIA: - Previous hepatitis C treatment - Pregnant women or partners of pregnant women - Patients or partners of patients who intend to become pregnant any time during the 48 weeks - Women who are breastfeeding - Individuals with liver disease not caused by hepatitis C - Individuals infected with the hepatitis B virus and/or human immunodeficiency virus (HIV) - Patients with a history of liver cancer (hepatocellular carcinoma) - Known blood disorders such as hemoglobinopathy, coagulopathy, or glucose-6-phosphate dehydrogenase [G6PD] deficiency - Body organ transplant - Any known or suspected cancer within the past 5 years - Individuals who currently use epoetin [EPO], granulocyte colony stimulating factor [G-CSF] and/or granulocyte monocyte colony stimulating factor [GM-CSF] - Those having a history of or active clinical gout - Individuals who have chronic pulmonary disease - Individuals who have a medical condition that would likely require systemic steroids - Those with a history of central nervous system (CNS trauma) or seizure disorders - Current or previous use of lithium or antipsychotic drugs - Individuals who currently have or show signs of moderate to severe depression or history of significant psychiatric disorders - Patients with clinically significant electrocardiogram (ECG) abnormalities - Individuals with serious heart problems such as those who have had a heart attack, uncontrolled high blood pressure, or other heart problems - Patients that weigh > 231-275 pounds (105-125 kg) AND have a body mass index (BMI) > 30 AND have 3 or more of the risk factors below: (a) Strong family history of coronary heart disease (CHD) which includes 2 or more first-degree relatives with CHD or family history of early CHD at age < 55 for male relatives or < 65 for female relatives (b) Individuals with abnormal total cholesterol and/or sub fractions (uncontrolled hypercholesterolemia) (c) Diabetes (d) Hypertension (e) Smoking", "gender": "All", "minimum_age": "18 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "mesh_term": ["Hepatitis", "Hepatitis A", "Hepatitis C", "Hepatitis, Chronic", "Hepatitis C, Chronic", "Ribavirin", "Peginterferon alfa-2b", "Interferon-alpha", "Peginterferon alfa-2a"], "id": "NCT00081770"}